Rezolute Bio
  • Investors & Media
    • Overview
    • Corporate Presentation
    • News
    • Events
    • Stock Quote and Chart
      • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info
  • Contact Us
  • Therapeutic Focus
    • Pipeline
    • RZ358
    • RZ402
    • Publications
    • Data Presentations
  • For Patients
    • Overview
    • Living with HI
    • Living with DME
  • About
    • Our Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Join Us
    • Our Mission
    • Open Positions
    • Benefits
  • Contact Us
  • Investors & Media
    • Overview
    • Corporate Presentation
    • News
    • Events
    • Stock Quote and Chart
      • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info

Press Releases

  • News & Events

  • Overview
  • IR Calendar
Oct 09, 2020 8:30am EDT

Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-list to Nasdaq

Sep 10, 2020 8:00am EDT

Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe Fauchet to its Board of Directors

Jul 27, 2020 8:00am EDT

Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism

Jun 15, 2020 8:30am EDT

Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science

Jun 10, 2020 8:30am EDT

Rezolute Receives Rare Pediatric Disease Designation for RZ358, Phase 2b Candidate for the Treatment of Congenital Hyperinsulinism, Enabling Eligibility for Priority Review Voucher

Jun 01, 2020 8:30am EDT

Rezolute Presents RZ358 Clinical Data-Validated Model of the Pharmacokinetics and Glycemic Response in Congenital Hyperinsulinism at Pediatric Endocrine Society 2020 Annual Meeting

May 28, 2020 8:30am EDT

Rezolute to Present Clinical Data for RZ358, Lead Candidate in Phase 2b Trial in Congenital Hyperinsulinism at Virtual Pediatric Endocrine Society 2020 Annual Meeting

May 14, 2020 4:15pm EDT

Rezolute, Inc. Announces Updates to Clinical and Business Operations in Response to COVID-19 Pandemic

Feb 10, 2020 8:30am EST

Rezolute Initiates Phase 2b Clinical Trial of Lead Candidate RZ358 in Congenital Hyperinsulinism

Jan 27, 2020 8:30am EST

Rezolute to Present at BIO CEO & Investor Conference 2020

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …12
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
rezolute logo

©2023 Rezolute, Inc.

Explore

  • Therapeutic Focus
  • For Patients
  • About
  • Join Us
  • Contact Us
  • Investors & Media

Contact

Corporate Headquarters

275 Shoreline Drive
Suite 500
Redwood City, CA 94065
+1 (650) 206-4507
info@rezolutebio.com

Investor Relations

Investor Relations Contacts

Legal

  • Terms of Use
  • Privacy Policy
MENU
  • Therapeutic Focus
    • Pipeline
    • RZ358
    • RZ402
    • Publications
    • Data Presentations
  • For Patients
    • Overview
    • Living with HI
    • Living with DME
  • About
    • Our Mission
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Join Us
    • Our Mission
    • Open Positions
    • Benefits
  • Contact Us
  • Investors & Media
    • Overview
    • Corporate Presentation
    • News & Events
    • Stock Quote and Chart
      • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info